Myocardial contrast echocardiography: Reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent

Mario Meza, Yigal Greener, Roberta Hunt, Bret Perry, Susan Revall, Wayne Barbee, Joseph P Murgo, Jorge Cheirif

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Reliable and reproducible myocardial opacification after intravenous administration of echocardiographic contrast agents has remained elusive. This study was performed to determine whether a new agent, FS069, a suspension of perfluoropropane-filled albumin microspheres (3.6 μm average microbubble size, concentration 8 x 88/ml), could achieve safe and successful myocardial opacification in open-chest dogs. Seventeen dogs (group 1, n = 7, group 2, n = 10) underwent two-dimensional echocardiography before, during, and after the administration of intravenous FS069. Safety was evaluated by measuring arterial and pulmonary artery pressures, heart rate, blood gases, systolic function, myocardial blood flow, and postmortem analysis of myocardial viability by triphenyl-tetrazolium chloride staining. Efficacy to detect changes in regional myocardial perfusion was assessed by injecting FS069 at baseline, after sequential coronary occlusions and reperfusion, and during intravenous vasodilators with and without coronary occlusions. Results were compared with radiolabeled microspheres. FS069 was found to be safe and effective. In the absence of coronary occlusions, uniform myocardial opacification was observed in all dogs. A perfusion defect was observed in all dogs during coronary occlusions. Background-subtracted peak contrast intensity in the myocardium correctly identified regional myocardial blood flow changes and showed a significant correlation with radiolabeled microspheres (r = 0.65, p = 0.0001).

Original languageEnglish (US)
Pages (from-to)871-881
Number of pages11
JournalAmerican Heart Journal
Volume132
Issue number4
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Coronary Occlusion
Intravenous Injections
Contrast Media
Echocardiography
Perfusion
Microspheres
Dogs
perflutren
Intravenous Administration
Microbubbles
Myocardial Reperfusion
Regional Blood Flow
Vasodilator Agents
Pulmonary Artery
Chlorides
Albumins
Suspensions
Myocardium
Thorax
Heart Rate

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Myocardial contrast echocardiography : Reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent. / Meza, Mario; Greener, Yigal; Hunt, Roberta; Perry, Bret; Revall, Susan; Barbee, Wayne; Murgo, Joseph P; Cheirif, Jorge.

In: American Heart Journal, Vol. 132, No. 4, 1996, p. 871-881.

Research output: Contribution to journalArticle

Meza, Mario ; Greener, Yigal ; Hunt, Roberta ; Perry, Bret ; Revall, Susan ; Barbee, Wayne ; Murgo, Joseph P ; Cheirif, Jorge. / Myocardial contrast echocardiography : Reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent. In: American Heart Journal. 1996 ; Vol. 132, No. 4. pp. 871-881.
@article{ec8782e74e5141338b658810c5da368e,
title = "Myocardial contrast echocardiography: Reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent",
abstract = "Reliable and reproducible myocardial opacification after intravenous administration of echocardiographic contrast agents has remained elusive. This study was performed to determine whether a new agent, FS069, a suspension of perfluoropropane-filled albumin microspheres (3.6 μm average microbubble size, concentration 8 x 88/ml), could achieve safe and successful myocardial opacification in open-chest dogs. Seventeen dogs (group 1, n = 7, group 2, n = 10) underwent two-dimensional echocardiography before, during, and after the administration of intravenous FS069. Safety was evaluated by measuring arterial and pulmonary artery pressures, heart rate, blood gases, systolic function, myocardial blood flow, and postmortem analysis of myocardial viability by triphenyl-tetrazolium chloride staining. Efficacy to detect changes in regional myocardial perfusion was assessed by injecting FS069 at baseline, after sequential coronary occlusions and reperfusion, and during intravenous vasodilators with and without coronary occlusions. Results were compared with radiolabeled microspheres. FS069 was found to be safe and effective. In the absence of coronary occlusions, uniform myocardial opacification was observed in all dogs. A perfusion defect was observed in all dogs during coronary occlusions. Background-subtracted peak contrast intensity in the myocardium correctly identified regional myocardial blood flow changes and showed a significant correlation with radiolabeled microspheres (r = 0.65, p = 0.0001).",
author = "Mario Meza and Yigal Greener and Roberta Hunt and Bret Perry and Susan Revall and Wayne Barbee and Murgo, {Joseph P} and Jorge Cheirif",
year = "1996",
doi = "10.1016/S0002-8703(96)90324-5",
language = "English (US)",
volume = "132",
pages = "871--881",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Myocardial contrast echocardiography

T2 - Reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent

AU - Meza, Mario

AU - Greener, Yigal

AU - Hunt, Roberta

AU - Perry, Bret

AU - Revall, Susan

AU - Barbee, Wayne

AU - Murgo, Joseph P

AU - Cheirif, Jorge

PY - 1996

Y1 - 1996

N2 - Reliable and reproducible myocardial opacification after intravenous administration of echocardiographic contrast agents has remained elusive. This study was performed to determine whether a new agent, FS069, a suspension of perfluoropropane-filled albumin microspheres (3.6 μm average microbubble size, concentration 8 x 88/ml), could achieve safe and successful myocardial opacification in open-chest dogs. Seventeen dogs (group 1, n = 7, group 2, n = 10) underwent two-dimensional echocardiography before, during, and after the administration of intravenous FS069. Safety was evaluated by measuring arterial and pulmonary artery pressures, heart rate, blood gases, systolic function, myocardial blood flow, and postmortem analysis of myocardial viability by triphenyl-tetrazolium chloride staining. Efficacy to detect changes in regional myocardial perfusion was assessed by injecting FS069 at baseline, after sequential coronary occlusions and reperfusion, and during intravenous vasodilators with and without coronary occlusions. Results were compared with radiolabeled microspheres. FS069 was found to be safe and effective. In the absence of coronary occlusions, uniform myocardial opacification was observed in all dogs. A perfusion defect was observed in all dogs during coronary occlusions. Background-subtracted peak contrast intensity in the myocardium correctly identified regional myocardial blood flow changes and showed a significant correlation with radiolabeled microspheres (r = 0.65, p = 0.0001).

AB - Reliable and reproducible myocardial opacification after intravenous administration of echocardiographic contrast agents has remained elusive. This study was performed to determine whether a new agent, FS069, a suspension of perfluoropropane-filled albumin microspheres (3.6 μm average microbubble size, concentration 8 x 88/ml), could achieve safe and successful myocardial opacification in open-chest dogs. Seventeen dogs (group 1, n = 7, group 2, n = 10) underwent two-dimensional echocardiography before, during, and after the administration of intravenous FS069. Safety was evaluated by measuring arterial and pulmonary artery pressures, heart rate, blood gases, systolic function, myocardial blood flow, and postmortem analysis of myocardial viability by triphenyl-tetrazolium chloride staining. Efficacy to detect changes in regional myocardial perfusion was assessed by injecting FS069 at baseline, after sequential coronary occlusions and reperfusion, and during intravenous vasodilators with and without coronary occlusions. Results were compared with radiolabeled microspheres. FS069 was found to be safe and effective. In the absence of coronary occlusions, uniform myocardial opacification was observed in all dogs. A perfusion defect was observed in all dogs during coronary occlusions. Background-subtracted peak contrast intensity in the myocardium correctly identified regional myocardial blood flow changes and showed a significant correlation with radiolabeled microspheres (r = 0.65, p = 0.0001).

UR - http://www.scopus.com/inward/record.url?scp=0029956720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029956720&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(96)90324-5

DO - 10.1016/S0002-8703(96)90324-5

M3 - Article

C2 - 8831379

AN - SCOPUS:0029956720

VL - 132

SP - 871

EP - 881

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -